Latigo Biotherapeutics, Inc. Company Profile
Latigo Biotherapeutics, Inc. as SEC EDGAR records it: incorporation, addresses, industry, fiscal year end, filer category and former names.
- Current registered country: Value Delaware, United States.
- Country of operation (business address): Value United States.
- Business address: Value 1300 RANCHO CONEJO BLVD., SUITE 305, THOUSAND OAKS, California, United States.
- Mailing address: Value 1300 RANCHO CONEJO BLVD., SUITE 305, THOUSAND OAKS, California, United States.
| Measure | Value |
|---|---|
| Current registered country | Delaware, United States SEC EDGAR state of incorporation DE |
| Country of operation (business address) | United States |
| Business address | 1300 RANCHO CONEJO BLVD., SUITE 305, THOUSAND OAKS, California, United States |
| Mailing address | 1300 RANCHO CONEJO BLVD., SUITE 305, THOUSAND OAKS, California, United States |
| Industry (SIC) | 2834 Pharmaceutical Preparations |
| Fiscal year end | 12-31 |
| Filer category | Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company |
| Listed stock (Section 12(b)) | Common Stock, par value $0.0001 per share · LTGO · The Nasdaq Global Select Market 10-Q filed 2026-09-03 cover |
| Shell company | No 10-Q filed 2026-09-03 cover |
| Smaller reporting company | Yes 10-Q filed 2026-09-03 cover |
| Emerging growth company | Yes 10-Q filed 2026-09-03 cover |
| Current in its reporting | No 10-Q filed 2026-09-03 cover |
| First EDGAR filing | 2025-02-13 (D) |
| SEC CIK | 2056611 |
| EIN | 832625838 |
| Phone | 805-716-2927 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |